OncoMed Pharmaceuticals Inc. will present new data related to its clinical and preclinical anti-cancer stem cell and immuno-oncology candidates in a total of seven presentations at the upcoming American Association of Cancer Research Meeting to be held April 18-22, 2015 in Philadelphia, PA. Among the presentations will be data looking at synergies between anti-DLL4 and anti-PD1 antibodies, as well as between Wnt-pathway inhibitors and taxanes; biomarker research for tarextumab , brontictuzumab and anti-RSPO3; and research related to the Hippo anti-cancer stem cell pathway.
http://ift.tt/1H3wRHR
http://ift.tt/1H3wRHR
No comments:
Post a Comment